Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Next Previous
Trial Profile

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 8968 (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

Most Recent Events

  • 21 Jul 2016 Status changed from completed to discontinued as no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.)
  • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 30 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top